• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by General Counsel Garcia Ruben A

    12/30/24 4:18:32 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBLG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GARCIA RUBEN A

    (Last) (First) (Middle)
    C/O FIBROBIOLOGICS, INC.
    455 E. MEDICAL CENTER BLVD., SUITE 300

    (Street)
    HOUSTON, TX 77598

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    FibroBiologics, Inc. [ FBLG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    General Counsel
    3. Date of Earliest Transaction (Month/Day/Year)
    12/27/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $2.36 12/27/2024 A 176,200 (1) 12/26/2034 Common Stock 176,200 $0 176,200 D
    Explanation of Responses:
    1. On December 27, 2024, the reporting person was granted an option to purchase 176,200 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.
    /s/ Ruben A. Garcia 12/30/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FBLG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FBLG

    DatePrice TargetRatingAnalyst
    12/12/2024$12.00Buy
    Rodman & Renshaw
    10/30/2024$12.00Buy
    H.C. Wainwright
    9/24/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $FBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      8/12/24 9:58:49 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Khoja Hamid bought $19,000 worth of shares (10,000 units at $1.90), increasing direct ownership by 800% to 11,250 units (SEC Form 4)

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      8/12/24 9:58:39 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Leadership Updates

    Live Leadership Updates

    See more
    • FibroBiologics Set to Join Russell 2000® Index

      HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b

      6/13/24 9:31:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Appoints Ruben A. Garcia as General Counsel

      HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel. He will report to Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer, and be an integral member of the executive leadership team.   "The addition of Ruben as our General Counsel rep

      3/6/24 9:31:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    SEC Filings

    See more
    • SEC Form 10-Q filed by FibroBiologics Inc.

      10-Q - FibroBiologics, Inc. (0001958777) (Filer)

      5/14/25 4:01:40 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Inc. filed SEC Form 8-K: Leadership Update

      8-K - FibroBiologics, Inc. (0001958777) (Filer)

      5/5/25 4:01:32 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by FibroBiologics Inc.

      DEFA14A - FibroBiologics, Inc. (0001958777) (Filer)

      4/23/25 6:05:38 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

      HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Senior Research Scientist, Dr. Chuo Fang M.D., Ph.D., delivered a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting that took place in San Diego May 7-10, 2025. The SID Annual Meeting provides a premier forum for skin biology research and education for researchers to share transformative scientific discoveries and medical inn

      5/16/25 8:30:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced first quarter 2025 financial results and provided a corporate update. Recent Highlights Announced the completion of FibroBiologics' proprietary master cell bank that will support upcoming clinical trials. Manufactured in accordance with FDA Good Manufacturing Practices (cGMP), the cell bank has successfully passed all required safety testing.Announced the opening of a new lab

      5/14/25 4:30:00 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Presenting at the ThymUS 2025 Meeting

      HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Simon Gebremeskel, research scientist at FibroBiologics, is presenting a poster at the ThymUS 2025 Meeting taking place in Lihue, Kaua'i Hawaii from April 27 - May 1, 2025. Founded in 2001, ThymUS brings together international researchers working on thymus and T-cell biology. The abstract entitled "A rapid and scalable thymus organoid development method for

      4/29/25 9:15:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Khoja Hamid

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      3/28/25 4:10:10 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by General Counsel Garcia Ruben A

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      3/28/25 4:10:13 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER O'Heeron Pete

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      3/28/25 4:10:14 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

      Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      12/12/24 8:54:24 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on FibroBiologics with a new price target

      H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      10/30/24 6:37:36 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on FibroBiologics with a new price target

      Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      9/24/24 7:59:12 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care